Filing Flows › Century Therapeutics (IPSC) › Q4 2024 › vs Q4 2023
Century Therapeutics (IPSC) Q4 2024 vs Q4 2023 (year over year)
Century Therapeutics's revenue rose $3.9M (16×) from $268K in Q4 2023 to $4.2M in Q4 2024.
Century Therapeutics, Q4 2024: revenue $4.2M (16× year over year), operating margin -893.5%, net loss $36.1M, operating cash flow −$24.2M. The chart draws each line against Q4 2023, the increases inside each band.
Every line
| Line | Q4 2024 | Q4 2023 | Change | % |
|---|---|---|---|---|
| Revenue | $4.2M | $268K | $3.9M | 16× |
| Other income, net | $3.0M | $3.5M | −$508K | -15% |
| Net loss | $36.1M | $39.4M | −$3.3M | -8% |
| Costs & expenses | $43.2M | $44.0M | −$797K | -2% |
| Operating costs | $41.5M | $44.0M | −$2.6M | -6% |
| Income tax | $1.8M | −$869K | $2.6M | — |
| Research & development | $29.4M | $22.3M | $7.1M | +32% |
| General & admin | $7.8M | $8.6M | −$834K | -10% |
| Other operating costs | $4.3M | $13.1M | −$8.8M | -67% |
| Operating cash sources | $36.1M | $39.4M | −$3.3M | -8% |
| Depreciation | $3.3M | $3.6M | −$234K | -7% |
| Share-based compensation | $2.7M | $3.6M | −$902K | -25% |
| Working capital & other | $5.9M | $6.1M | −$182K | -3% |
| Cash used in operations | $24.2M | $26.2M | −$2.0M | -8% |
| Net loss absorbed | $36.1M | $39.4M | −$3.3M | -8% |
Questions
How much did Century Therapeutics's revenue grow year over year in Q4 2024?
Century Therapeutics's revenue rose $3.9M (16×) from $268K in Q4 2023 to $4.2M in Q4 2024.